International Conference, AstraZeneca presented results on its interleukin-33 (IL-33) inhibitor, tozorakimab, from its ...

AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises ...

AstraZeneca presented data from the phase 3 BATURA study which showed that use of Airsupra in those with mild asthma reduced ...

AstraZeneca will present the latest clinical and real-world ... chronic bronchitis and smoking status. • Tozorakimab: Demonstrating potential benefits of tozorakimab to reduce excess inflammation in ...

Partners Regeneron and Sanofi say itepekimab only achieved a significantly statistic result in one of two studies.

WILMINGTON, Del., May 13, 2025--(BUSINESS WIRE)--AstraZeneca will present the latest clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at ...

AstraZeneca, as part of its ongoing $3.5 billion investment in American innovation, opened its first U.S.-operated cell therapy factory in Maryland to help treat cancer patients. The U.K-based ...

HEADQUARTERS IN ROCKVILLE. THIS LAB ISN’T OPEN OR OPERATIONAL YET, BUT ONCE IT IS, THE FOLKS AT ASTRAZENECA BELIEVE IT IS GOING TO REVOLUTIONIZE CANCER TREATMENT. IT GIVES US HOPE. I MEAN.

State officials and AstraZeneca marked the opening Monday of a cell therapy facility in Rockville that aims to create pathways to jobs for the state’s STEM professionals. AstraZeneca completed a ...